Disease Associations: Articles are linked to genes based on NCBI's Gene <-> Pubmed associations (human and mouse orthologs). Genes are linked to diseases based on the presence of keywords in the Abstract or MeSH Terms of Pubmed entries. Click to see the list of Abstract and MeSH terms.

Pathway: associated pathways from the Reactome database

Summary: Swissprot summary of protein function

Inhibitors: Small molecule modulators from the published and patent literature

compounds with MW < 1000 Da and at least 6 carbons complexed to target of interest

Substrates: Published substrate specificity

Search Gene: Targets that contain the keyword in either the name or synonyms will be highlighted.

Domain Architecture: PFAM domains identified by using HMMER-3.0 on the protein sequences (downloadable from a link at the top of the tree) against the PFAM database, with an Evalue threshold of 0.01

Antigen: Antigens have been cloned, expressed and purified at SGC for FAb/IgG production.

FAb: At least one FAb has been validated at SGC for this antigen.

IgG: At least one IgG has been validated at SGC for this antigen.

PubMed: Articles linked to the NCBI's Entrez Gene record of the human, mouse and rat orthologs. Articles linked to 30 or more genes (typically sequencing or microarray data) are ignored.

Protein Interactions: Interaction network from http://www.string-db.org

Protein Interactome: data from http://www.ncbi.nlm.nih.gov/pubmed/25416956

Subcellular location: Subcellular location extracted from the Swiss-Prot record of each gene

Structures: Structure coverage generated by blasting the protein sequence (downloadable from a link at the top of the tree) against the PDB with a sequence identity cut-off of 95% and minimum coverage of 30 residues

Non-silent SNPs: Natural variations extracted from www.uniprot.org/docs/humsavar.

Gene essentiality in cancer: derived from CRISPR knock-out in 341 [Broad] and 320 [Sanger] cell lines from 30 cancer types, and RNAi knock-down in 570 cancer cell lines from 46 cancer types. The gene is essential in a given cell line if the CRISPR Score < -1.0 [Broad] or its corrected log fold change (i.e. average sgRNA representation at the beginning versus end of the experiment) < -0.5 [Sanger]. Similarly, lower RNAi scores (i.e Demeter2 scores), mean higher essentiality in cancer. Numbers shown are median values of essentiality scores for all cell lines representing a given cancer type. CRIPSR data from https://portals.broadinstitute.org/achilles (Meyers et al. Nature Genetics 2017. DOI: 10.1038/ng.3984) and https://score.depmap.sanger.ac.uk (Behan et al. Nature 2019. DOI 10.1038/s41586-019-1103-9). RNAi/DEMETER2 data from https://depmap.org/R2-D2/ (McFarland et al. Nature Comm. 2018 DOI: 10.1038/s41467-018-06916-5)

Gene essentiality in cancer: derived from CRISPR knock-out in 341 [Broad] and 320 [Sanger] cell lines from 30 cancer types, and RNAi knock-down in 570 cancer cell lines from 46 cancer types. The gene is essential in a given cell line if the CRISPR Score < -1.0 [Broad] or its corrected log fold change (i.e. average sgRNA representation at the beginning versus end of the experiment) < -0.5 [Sanger]. Similarly, lower RNAi scores (i.e Demeter2 scores), mean higher essentiality in cancer. Numbers shown are median values of essentiality scores for all cell lines representing a given cancer type. CRIPSR data from https://portals.broadinstitute.org/achilles (Meyers et al. Nature Genetics 2017. DOI: 10.1038/ng.3984) and https://score.depmap.sanger.ac.uk (Behan et al. Nature 2019. DOI 10.1038/s41586-019-1103-9). RNAi/DEMETER2 data from https://depmap.org/R2-D2/ (McFarland et al. Nature Comm. 2018 DOI: 10.1038/s41467-018-06916-5)

Gene Fusions in Cancer: Data extracted from the August 18, 2014 version of the Mitelman database.

Chromosomal Aberrations in Cancer: Data extracted from the November 4th 2014 version of the Cancer Gene Census.